Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

This trial (n=697) did not meet its primary endpoint of improving progression-free survival with avelumab plus chemoradiotherapy followed by avelumab maintenance compared with placebo plus chemoradiotherapy followed by placebo maintenance.

Source:

The Lancet Oncology